CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial
Open Access
- 12 January 2012
- journal article
- research article
- Published by Springer Science and Business Media LLC in British Journal of Cancer
- Vol. 106 (4), 633-637
- https://doi.org/10.1038/bjc.2011.593
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-studyAnnals of Oncology, 2011
- Decreased hypersensitivity reactions with carboplatin-pegylated liposomal doxorubicin compared to carboplatin-paclitaxel combination: Analysis from the GCIG CALYPSO relapsing ovarian cancer trialGynecologic Oncology, 2011
- Early Decline in Cancer Antigen 125 as a Surrogate for Progression-Free Survival in Recurrent Ovarian CancerJNCI Journal of the National Cancer Institute, 2011
- Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trialThe Lancet, 2010
- Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late RelapseJournal of Clinical Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal Of Cancer, 2009
- Clinical trial endpoints in ovarian cancer: Report of an FDA/ASCO/AACR Public WorkshopGynecologic Oncology, 2007
- Comparison of CA-125 and Standard Definitions of Progression of Ovarian Cancer in the Intergroup Trial of Cisplatin and Paclitaxel Versus Cisplatin and CyclophosphamideJournal of Clinical Oncology, 2006
- Worldwide burden of gynaecological cancer: The size of the problemBest Practice & Research Clinical Obstetrics & Gynaecology, 2005
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000